Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Randomised Controlled Trial to Assess the Efficacy of Adding Rituximab to Standard of Care in Treating Acute Antibody-mediated Rejection in Kidney Transplantation

NCT03994783 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT03994783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03994783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Randomised Controlled Trial to Assess the Efficacy of Adding Rituximab to Standard of Care in Treating Acute Antibody-mediated Rejection in Kidney Transplantation
Lead sponsor
Imperial College London
Phase
Phase 3
Overall status
Terminated
Start date
July 17, 2019
Completion date
January 9, 2023
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection, kidney transplant rejection